Jin S, et al. - In resected stage III non-small cell lung cancer (NSCLC), a precision cancer/testis antigen (CTA) profiling was sought. Researchers also investigated the best CTA combination which would cover the widest range of NSCLC cases. They assessed the expression of 10 CTAs in 200 resected stage III NSCLC tissue specimens at protein level. To demonstrate CTA expression and coverage, they used hierarchical clustering and python programming language analyses. They succeed at establishing an individualized CTA profiling in resected stage III NSCLC based on 10 CTA expression. Use of the least CTA combination based on sex, smoking history, and histology, helped reaching the goal of the maximum CTA expression coverage.